



Nemaura Medical, Inc.

Ticker: NMRD (OTCQB)

Page 1 of 2

Corporate Profile

as of September 21, 2017

Sector: Healthcare
Industry: Medical Devices and Technology

Website: www.nemauramedical.com

Nemaura Medical, Inc., (NMRD) or (the "Company") is a medical device/life sciences, research and development company with patent-protected technology. The Company, based in Loughborough Science Park of the United Kingdom (incorporated in Nevada), is focused on the development and commercialization of a new wireless disposable adhesive skin-patch for alternative use of glucose monitoring by diabetics.

Nemaura Medical has recently completed the development of their second-generation sugarBEAT® product line which consists of a disposable patch containing a sensor, and a non-disposable miniature electronic transmitter device with a disposable or re-chargeable power source. This device enables the detection of changes in blood glucose levels making it easier for diabetes patient users to monitor their blood sugar levels.

The Company plans on two CGM sugarBEAT® devices to reach the market soon. The first is a watch with a transmitter inside that is directly connected to a sensor using a wire. The second product is a body-worn transmitter patch device into which the sensor is directly attached, and transmits data directly to the Company developed smart phone app. SugarBEAT®, has received Conformité Européenne (CE) regulatory approval in Europe, and has ongoing clinical studies to support product launches in multiple territories including the Middle East, Australia and New Zealand.

The sugarBEAT® patch works by extracting glucose from the skin into the skin patch which is in direct contact with an electrode-based glucose sensor. The glucose sensor detects the level of glucose, stores the data on internal memory, and displays the glucose reading on an LCD display on a smart watch. With the patch transmitter device, the raw data is sent to a mobile phone app where it is processed algorithmically and displayed as a glucose reading and is read by the app vs the watch, depending on which the user finds more convenient. The devices have the ability to track and trend glucose data over days, weeks, and months. One of the techniques utilized in these devices, is reverse Ionotophoresis, (a type of electrical stimulation used to administer medicine to the body via the skin) which has been the subject of extensive studies with over 20 clinical studies.

Dr. Dewan F.H. Chowdhury, Chief Executive Officer, has led the Company since its founding in December, 2013. Dr. Chowdhury is the sole inventor of more than 50 granted and pending patents in over 15 technology areas in the medical device and pharmaceutical sectors. Dr. Chowdhury originally trained as a pharmaceutical scientist, holds an MSc degree from Cranfield University, and a Doctorate degree from the University of Oxford. His experience in the pharmaceutical industry includes product development; manufacturing; technical support and assistance, and corporate management. Prior to his role with Nemaura Medical, Inc., Dr. Chowdhury was the founder and CEO



sugarBeat® app displaying glucose levels on smart phone / Watch (future product under development)

Key Statistics

Table with 2 columns: Metric and Value. Rows include Price (09/20/2017) at \$5.12, 52 Week High at 9.60, 52 Week Low at 1.40, Avg. Vol (30day) at 5,439, Market Cap (Interday) at 1.05 B, Insider Ownership (%) at 67%, Shares Outstanding (M) at 205, Float (Th) at 67.67, and EPS(ttm) at -0.01.

Source: Google / Yahoo Finance

Recent 2017 Highlights

- August 29, 2017, the Company announced that it has completed development of a medical grade software app prepared and in compliance with ISO13485 quality standards. The app is designed to be used with the sugarBEAT® device or with third party glucose meters/strips to display glucose levels on users android mobile devices, with future plans for iOS users.
August 15, 2017, the Company announced it has signed a distribution agreement for sugarBEAT® with Device Technologies for Australia and New Zealand territories. Device Technologies is a leading medical device distribution firm.
August 1, 2017, the Company announced it has developed a slimmer sugarBEAT® transmitter with a built-in rechargeable battery that will reduce end user costs. The Company has plans to reduce costs for its test strips as well as meters in an effort to make sugarBEAT® affordable for all users.
June 12, 2017, the Company announced it has completed major improvements in its sugarBEAT® sensors performance. This major improvement is expected to enhance sugarBEAT®s accuracy by enabling users to better detect small fluctuations in glucose levels, and detect glucose at very low levels. The sugarBEAT® clinical trial program, involving up to 75 patients over 525 days, is due to commence by year end.
April 24, 2017, the Company announced it successfully completed development of its second-generation sugarBEAT® non-invasive continuous glucose monitoring skin-patch. The first patch received CE approval in Q1 2016, as a wired wrist-watch based non-invasive and needle-free CGM system.

The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to the accuracy or validity thereof. The information may include certain forward-looking statements within the meaning of Section 21E of the SEC Act of 1934, which may be affected by unforeseen circumstances or certain risks. Any investments in securities mentioned here contain inherent and significant risks, and are suitable only for speculative oriented investors. Any investments should only be made after consulting an investment professional. The featured company will pay a fee of \$7500 in cash to Alan Stone & Company LLC for preparation and distribution of this profile, including other potential fees associated with various consulting and investor relation services. For complete disclaimer information, the readers are hereby referred to the Disclaimer Page at the www.WallStreetResearch.org website.

**Nemaura Medical, Inc.**

Ticker: **NMRD** (OTCQB)

Page 2 of 2

**Corporate Profile**

as of September 21, 2017

Sector: Healthcare  
Industry: Medical Devices and Technology

Website: [www.nemauramedical.com](http://www.nemauramedical.com)

of both Microneedle Technologies, and Nemaura Pharma Limited where he played a pivotal role in the development, manufacturing and launch of a microneedle device used in skin clinics.

The Company's management team also consists of: Chief Financial Officer, Ian Anderson; Director of Strategy and Corporate Development, Mr. Bashir Timol; Director of Product Development, Professor Karrar Khan; Director of Commercial Development and Licensing, David Scott; and Technical and Business Development Manager, Dr. Richard Toon. The Company was up-listed to the OTCQB in July 2017, and has recently appointed three independent directors to the Board to strengthen its corporate governance.

The Company plans to implement a broad business strategy in order to market their products to select territories. Key commercial strategies and post regulatory-approval will first be implemented in Europe and then in parts of the Middle East and Asia, and subsequently in the USA. The Company plans to develop its own specialized sales and marketing teams to market the sugarBEAT® device in the European Union with a joint venture partner. The Company has a marketing rights agreement in place for the UK and Republic of Ireland (including the Isle of Man and the Channel Islands), with Dallas Burston Pharma (Jersey) Ltd. It has signed agreements to collaborate on the sale of the device in other European territories as part of the joint venture agreement. The full commercial agreement outlining the details of the joint venture agreement is expected to be finalized soon. Significant opportunities lie in the diabetes, athletic performance, intensive care, and wider diagnostics markets. With completion of clinical studies, Nemaura Medical, Inc. expects to be well positioned for future growth.



sugarBEAT® transmitter and patch shown to scale (future product under development)

On August 9, 2017, the Company reported First Quarter 2017 financial results for the June 30 period. Research and Development expenses fell to \$149,198 for the quarter ended June 2017, a decrease of 51% from \$306,081 for the same quarter in 2016. This decrease of \$156,883 is due to sugarBEAT® product development nearing completion. General and Administrative expenses increased to \$268,122 for the quarter ended June 2017, compared to \$188,102 for same quarter in 2016. The Company's Comprehensive Loss fell to \$205,032 for the three months ended June 30, 2017, a decrease of 80% from \$1,024,198 for the same quarter in 2016. As of June 30, 2017, the Company's combined cash and bank deposits (short and long-term) were \$7,111,493.

To continue the marketing and commercialization of its technology, and diversification into new applications, Nemaura Medical, Inc. is actively seeking partners, licensees and collaborators globally. With these new ventures, new potential products, and the anticipated beginning of product sales, Nemaura Medical, Inc. believes it will become an important player in the Diabetic segment of the medical device industry.

**Corporate Contact Information**

**Nemaura Medical Inc.,**  
Advanced Technology Centre  
Oakwood Drive  
Loughborough  
Leicestershire, UK  
LE11 3QF

Contact: Bashir Timol, Director  
Tel: +44 1509 222 912  
[www.NemauraMedical.com](http://www.NemauraMedical.com)  
[www.SugarBeat.com](http://www.SugarBeat.com)

Income Statement	YE March 31 2016	YE March 31 2017	QTR Ended June 30, 2017	Balance Sheet	As of March 31, 2016	As of March 31, 2017	QTR Ended June 30, 2017	Cash Flow Statement	YE March 31 2016	YE March 31 2017	QTR Ended June 30, 2017
Revenue	-	-	-	Cash & cash equivalents	9,403,965	2,779,309	2,579,343	Operating Cash Flow	(1,432,863)	(1,209,365)	(287,966)
Gross Profit	-	-	-	Total Assets	9,732,783	7,401,906	7,406,104	Investing Cash Flow	(6,740)	(87,564)	(635,092)
Operating Loss	(1,539,637)	(1,551,266)	(417,320)	Total Liabilities	2,054,018	2,035,406	2,244,636	Financing Cash Flow	-	10,299,434	-
Net Loss	(1,539,637)	(1,551,266)	(407,787)	Total Shareholder's Equity	7,678,765	5,366,500	5,161,468	Cash at end of period	354,749	9,403,965	2,579,343



Figure 2: NMRD 1 Year Price Chart



Figure 3: NMRD 2 Month Price Chart

The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to the accuracy or validity thereof. The information may include certain forward-looking statements within the meaning of Section 21E of the SEC Act of 1934, which may be affected by unforeseen circumstances or certain risks. Any investment in securities contains inherent risks and should only be done after consulting an investment professional. The featured company will pay a fee of \$7500 in cash to Alan Stone & Company LLC for preparation and distribution of this updated profile, plus other potential fees, including stock associated with various consulting and investor relation services. For complete disclaimer information, the readers are hereby referred to the Disclaimer Page at the [www.WallStreetResearch.org](http://www.WallStreetResearch.org) website.